TransMedics

While TransMedics Group Inc may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 21% discount to our quantitative fair value estimate of $105.09 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's solid growth strengthens our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 57.0% sits in the top 10% compared with global peers. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

Conversely, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 18.7%, for example, sits in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.